ESMO18: Bristol-Myers Squibb eyes lead in rare colorectal cancer with new Opdivo results

opdivo
BMS presented Opdivo-Yervoy data on first-line colorectal cancer at ESMO. (Bristol-Myers Squibb)

MUNICH—Bristol-Myers Squibb is looking to push its Opdivo-Yervoy combo further into colorectal cancer, and with new phase 2 data in previously untreated patients, it just might be able to.

Monday at the European Society for Medical Oncology annual meeting, the New Jersey drugmaker rolled out results showing that its immuno-oncology duo provoked responses in 60% of previously untreated patients with metastatic colorectal cancer that’s microsatellite instability-high (MSI-H) or mismatch repair deficient. About 4-5% of mCRC patients have those biomarkers, which make them less likely to benefit from conventional chemo.

Fouad Namouni, Bristol-Myers’ oncology development chief, called the study “groundbreaking,” and noted that in previous trials, PD-1 agents posted response numbers “in the mid-to-high 30s.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Adding CTLA4 drug Yervoy almost doubled the response rate, which “hopefully will translate into a longer-term benefit with a manageable safety profile,” he said.

DOWNLOAD THE FULL ESMO 2018 CONFERENCE REPORT

So far, the FDA has doled out three approvals in MSI-H cancers, though they’ve all been for previously treated patients. Merck was the first to win one, snagging a nod for its PD-1 player Keytruda last May that covered MSI-H tumors of any kind—not just colorectal—identified anywhere in the body with genetic testing.

Bristol followed with a more limited, colorectal-only OK for solo Opdivo in August, and it added a combo approval for Opdivo and Yervoy this July.

The new data, though, give the company a chance at earlier use, which generally comes along with a wider patient population that stays on treatment for longer. And Bristol, which recently ceded the immuno-oncology sales lead to its archrival Merck, wouldn’t mind that opportunity.

RELATED: The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 sales

Meanwhile, BMS is trialing its one-two punch in several other cancer types, many of which it showcased at ESMO. The pharma giant trotted out positive data in melanoma, kidney cancer and bladder cancer, and it’s expecting phase 3 results in lung cancer, head and neck cancer, liver cancer in more in the not-too-distant future.

And while the Opdivo-Yervoy combo so far hasn’t lived up to Merck’s Keytruda-chemo pairing in the all-important lung cancer field, BMS has remained adamant that it's on the right track.

“My vision of the treatment of cancer, it’s not going to be one or two agents,” Namouni said. “I really think we’re going to have to combine a number of modalities together in a rational way … to raise the bar.”

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.